about
The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.Maintaining consistent quality and clinical performance of biopharmaceuticals.Extrapolation concept at work with biosimilar: a decade of experience in oncology.The Path Towards a Tailored Clinical Biosimilar DevelopmentBiosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodiesThe Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal
P50
description
researcher
@en
name
Martin Schiestl
@en
type
label
Martin Schiestl
@en
prefLabel
Martin Schiestl
@en
P31
P496
0000-0001-5784-9951